Omecamtiv mecarbil: A myosin motor activator agent with promising clinical performance and new in vitro results

P. Nánási, I. Komáromi, Marta Gaburjakova, János Almássy

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background: Clinical treatment of heart failure is still suffering from limited efficacy and unfavorable side effects. The recently developed group of agents, the myosin motor activators, act directly on cardiac myosin resulting in an increased force generation and prolongation of contraction. The lead molecule, omecamtiv mecarbil is now in human 3 stage. In addition to the promising clinical data published so far, there are new in vitro results indicating that the effect of omecamtiv mecarbil on contractility is rate-dependent. Furthermore, omecamtiv mecarbil was shown to activate cardiac ryanodine receptors, an effect that may carry proarrhythmic risk. Methods: These new results, together with the controversial effects of the drug on cardiac oxygen consumption, are critically discussed in this review in light of the current literature on omecamtiv mecarbil. Results: In therapeutically relevant concentrations the beneficial inotropic effect of the agent is not likely affected by these new results-in accordance with the good clinical data. At supratherapeutic concentrations, however, activation of cardiac ryanodine receptors may increase arrhythmia propensity, and the stronger effect on diastolic than systolic cell shortening, observed at higher pacing frequencies, may decrease or offset the inotropic effect of omecamtiv mecarbil. Conclusion: Further studies with definitely supratherapeutical concentrations of omecamtiv mecarbil should be designed to map the actual risk of these potentially harmful side-effects.

Original languageEnglish
Pages (from-to)1720-1728
Number of pages9
JournalCurrent Medicinal Chemistry
Volume25
Issue number15
DOIs
Publication statusPublished - Nov 29 2017

Fingerprint

Myosins
Ryanodine Receptor Calcium Release Channel
Cardiac Myosins
Treatment Failure
Oxygen Consumption
In Vitro Techniques
omecamtiv mecarbil
Cardiac Arrhythmias
Heart Failure
Chemical activation
Oxygen
Molecules
Pharmaceutical Preparations

Keywords

  • Cytosolic Ca
  • Heart failure
  • Inotropic agents
  • Myosin activators
  • Omecamtiv mecarbil
  • Ryanodine receptor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Omecamtiv mecarbil : A myosin motor activator agent with promising clinical performance and new in vitro results. / Nánási, P.; Komáromi, I.; Gaburjakova, Marta; Almássy, János.

In: Current Medicinal Chemistry, Vol. 25, No. 15, 29.11.2017, p. 1720-1728.

Research output: Contribution to journalReview article

@article{1eb1c46a895f4d4fa170525395bdacee,
title = "Omecamtiv mecarbil: A myosin motor activator agent with promising clinical performance and new in vitro results",
abstract = "Background: Clinical treatment of heart failure is still suffering from limited efficacy and unfavorable side effects. The recently developed group of agents, the myosin motor activators, act directly on cardiac myosin resulting in an increased force generation and prolongation of contraction. The lead molecule, omecamtiv mecarbil is now in human 3 stage. In addition to the promising clinical data published so far, there are new in vitro results indicating that the effect of omecamtiv mecarbil on contractility is rate-dependent. Furthermore, omecamtiv mecarbil was shown to activate cardiac ryanodine receptors, an effect that may carry proarrhythmic risk. Methods: These new results, together with the controversial effects of the drug on cardiac oxygen consumption, are critically discussed in this review in light of the current literature on omecamtiv mecarbil. Results: In therapeutically relevant concentrations the beneficial inotropic effect of the agent is not likely affected by these new results-in accordance with the good clinical data. At supratherapeutic concentrations, however, activation of cardiac ryanodine receptors may increase arrhythmia propensity, and the stronger effect on diastolic than systolic cell shortening, observed at higher pacing frequencies, may decrease or offset the inotropic effect of omecamtiv mecarbil. Conclusion: Further studies with definitely supratherapeutical concentrations of omecamtiv mecarbil should be designed to map the actual risk of these potentially harmful side-effects.",
keywords = "Cytosolic Ca, Heart failure, Inotropic agents, Myosin activators, Omecamtiv mecarbil, Ryanodine receptor",
author = "P. N{\'a}n{\'a}si and I. Kom{\'a}romi and Marta Gaburjakova and J{\'a}nos Alm{\'a}ssy",
year = "2017",
month = "11",
day = "29",
doi = "10.2174/0929867325666171222164320",
language = "English",
volume = "25",
pages = "1720--1728",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

TY - JOUR

T1 - Omecamtiv mecarbil

T2 - A myosin motor activator agent with promising clinical performance and new in vitro results

AU - Nánási, P.

AU - Komáromi, I.

AU - Gaburjakova, Marta

AU - Almássy, János

PY - 2017/11/29

Y1 - 2017/11/29

N2 - Background: Clinical treatment of heart failure is still suffering from limited efficacy and unfavorable side effects. The recently developed group of agents, the myosin motor activators, act directly on cardiac myosin resulting in an increased force generation and prolongation of contraction. The lead molecule, omecamtiv mecarbil is now in human 3 stage. In addition to the promising clinical data published so far, there are new in vitro results indicating that the effect of omecamtiv mecarbil on contractility is rate-dependent. Furthermore, omecamtiv mecarbil was shown to activate cardiac ryanodine receptors, an effect that may carry proarrhythmic risk. Methods: These new results, together with the controversial effects of the drug on cardiac oxygen consumption, are critically discussed in this review in light of the current literature on omecamtiv mecarbil. Results: In therapeutically relevant concentrations the beneficial inotropic effect of the agent is not likely affected by these new results-in accordance with the good clinical data. At supratherapeutic concentrations, however, activation of cardiac ryanodine receptors may increase arrhythmia propensity, and the stronger effect on diastolic than systolic cell shortening, observed at higher pacing frequencies, may decrease or offset the inotropic effect of omecamtiv mecarbil. Conclusion: Further studies with definitely supratherapeutical concentrations of omecamtiv mecarbil should be designed to map the actual risk of these potentially harmful side-effects.

AB - Background: Clinical treatment of heart failure is still suffering from limited efficacy and unfavorable side effects. The recently developed group of agents, the myosin motor activators, act directly on cardiac myosin resulting in an increased force generation and prolongation of contraction. The lead molecule, omecamtiv mecarbil is now in human 3 stage. In addition to the promising clinical data published so far, there are new in vitro results indicating that the effect of omecamtiv mecarbil on contractility is rate-dependent. Furthermore, omecamtiv mecarbil was shown to activate cardiac ryanodine receptors, an effect that may carry proarrhythmic risk. Methods: These new results, together with the controversial effects of the drug on cardiac oxygen consumption, are critically discussed in this review in light of the current literature on omecamtiv mecarbil. Results: In therapeutically relevant concentrations the beneficial inotropic effect of the agent is not likely affected by these new results-in accordance with the good clinical data. At supratherapeutic concentrations, however, activation of cardiac ryanodine receptors may increase arrhythmia propensity, and the stronger effect on diastolic than systolic cell shortening, observed at higher pacing frequencies, may decrease or offset the inotropic effect of omecamtiv mecarbil. Conclusion: Further studies with definitely supratherapeutical concentrations of omecamtiv mecarbil should be designed to map the actual risk of these potentially harmful side-effects.

KW - Cytosolic Ca

KW - Heart failure

KW - Inotropic agents

KW - Myosin activators

KW - Omecamtiv mecarbil

KW - Ryanodine receptor

UR - http://www.scopus.com/inward/record.url?scp=85048878557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048878557&partnerID=8YFLogxK

U2 - 10.2174/0929867325666171222164320

DO - 10.2174/0929867325666171222164320

M3 - Review article

C2 - 29278207

AN - SCOPUS:85048878557

VL - 25

SP - 1720

EP - 1728

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 15

ER -